论文部分内容阅读
目的:研究通心络对血管紧张素Ⅱ(AngⅡ)诱导的人脐静脉内皮细胞(human umbilical vein endotheli-alcells,HUVECs)细胞活力(cell viability)及组织因子(tissue factor,TF)的影响和其作用机制。方法:分别用5%,10%,20%的通心络含药血浆预处理内皮细胞30min后加入AngⅡ10-6mol/L孵育HUVECs24h,观察细胞活力变化的量效关系。选择一个最佳浓度的通心络含药血浆预处理内皮细胞30min后加入AngⅡ10-6mol/L孵育HU-VECs24h观察TF,AngⅡ1型受体(AT1) mRNA水平,一氧化氮合酶(NOS)活性及一氧化氮浓度(NO),并予NOS抑制剂(L-NAME)预处理内皮细胞30min后,再加入通心络含药血浆和AngⅡ,观察孵育24h细胞活力,TF,AT1,NOS及NO变化。结果:通心络能显著提高AngⅡ诱导的血管内皮细胞活力,以10%浓度作用最明显,通心络能降低TF及AT1水平及提高NOS活性和NO浓度;L-NAME可明显抑制通心络对血管内皮的作用。结论:通心络可能通过上调NOS-NO通路提高AngⅡ诱导的内皮细胞活力及抗血栓能力。
Objective: To study the effects of Tongxinluo on the cell viability and tissue factor (TF) of human umbilical vein endotheli-alcells (HUVECs) induced by angiotensin II (AngII) and Mechanism. METHODS: After pretreatment of endothelial cells with 5%, 10%, and 20% Tongxinluo drug-containing plasma for 30 min, HUVECs were incubated with Ang II 10-6 mol/L for 24 h to observe the dose-effect relationship of cell viability changes. After an average concentration of Tongxinluo drug-containing plasma was used to pretreat endothelial cells for 30 minutes, AngII10-6mol/L was used to incubate HU-VECs for 24 hours to observe the expression of TF, AngII1 receptor (AT1) mRNA, and nitric oxide synthase (NOS) activity. After nitric oxide concentration (NO) was pretreated with NOS inhibitor (L-NAME) for 30 min, Tongxinluo drug-containing plasma and AngII were added to observe the 24-hour cell viability, TF, AT1, NOS and NO. Variety. RESULTS: Tongxinluo can significantly increase the activity of Ang II-induced vascular endothelial cells. The effect of Tongxinluo is the most obvious at 10%. Tongxinluo can reduce TF and AT1 levels and increase NOS activity and NO concentration; L-NAME can significantly inhibit Tongxinluo Effect on the vascular endothelium. Conclusion: Tongxinluo may improve the AngII-induced endothelial cell viability and anti-thrombotic ability by up-regulating NOS-NO pathway.